SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will report third quarter 2017 financial results after the close of U.S. financial markets on November 8, 2017. Cidara’s management will host a webcast and conference call at 4:05 p.m. EST/1:05 p.m. PST that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 844-358-8763 for domestic callers, or 703-736-7375 for international callers, and use the conference ID # 2899958. The webcast will be made available on Cidara’s website at www.cidara.com under the News and Events tab in the Investors section. Following the live audio webcast, a replay will be available on Cidara's website for approximately 30 days.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antibiotic immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings. CD101 IV is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara has received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of CD201 and back-up candidates. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Robert H. Uhl
Westwicke Partners, LLC
Sam Brown Inc.
Source:Cidara Therapeutics, Inc.